Secukinumab improves skin response in Chinese patients with psoriatic arthritis
Secukinumab linked to skin improvement in Chinese psoriatic arthritis patients
This observational cohort study of 446 Chinese patients with psoriatic arthritis found that treatment with secukinumab for over 12 weeks was…
In Chinese psoriatic arthritis patients, secukinumab treatment was associated with significant skin improvement and better quality of life o…
Secukinumab 300 mg subcutaneously failed to demonstrate overall response in adults with active Graves orbitopathy versus placebo.
Secukinumab showed no benefit for active Graves orbitopathy patients
This randomized, double-blind, placebo-controlled trial evaluated secukinumab versus placebo in 28 adults with active, moderate-to-severe, n…
Secukinumab treatment for Graves orbitopathy showed no improvement in symptoms or eye measurements compared to placebo treatment.
FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older
The FDA has approved a new drug called Cosentyx for treating a serious skin condition.
The FDA approved Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older who are c…
The FDA approved Cosentyx for moderate to severe plaque psoriasis in adults and children 6 and older. It is a biologic drug that targets inf…
FDA Approves Cosentyx (secukinumab) for Moderate to Severe Hidradenitis Suppurativa in Adults and Pediatric Patients
The FDA approved a new use for the drug Cosentyx to treat a painful skin condition.
The FDA has approved Cosentyx for moderate to severe hidradenitis suppurativa in adults and pediatric patients 12 years and older. This inte…
The FDA has approved Cosentyx for treating moderate to severe hidradenitis suppurativa, a chronic skin condition that causes painful lumps. …
Case report describes secukinumab use in a woman with erythrodermic psoriasis and systemic capillary leak syndrome
One case report links secukinumab to severe capillary leak syndrome in a woman with psoriasis
This case report details the clinical course of a 66-year-old woman with new-onset erythrodermic psoriasis who developed systemic capillary …
A woman with psoriasis developed life-threatening capillary leak syndrome after starting secukinumab, with symptoms improving only after sto…
Secukinumab improves cutaneous adipose tissue inflammatory signatures in psoriasis patients.
Fat Under Your Skin Fuels Psoriasis Inflammation
This randomized placebo-controlled trial evaluated secukinumab in 82 patients with psoriasis. The study assessed changes in the cutaneous ad…
Your body fat is not just storing energy; it is actively making your psoriasis worse, and new treatments are finally targeting this hidden f…